Search

Your search keyword '"MESH: Eye Neoplasms"' showing total 3 results
Start Over Descriptor "MESH: Eye Neoplasms" Publisher hal ccsd
3 results on '"MESH: Eye Neoplasms"'

1. Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma

Author

Christian Berthou, Jean-Christophe Ianotto, Catherine Marianowski-Cochard, Adrian Tempescul, Olivier Pradier, Michel, Geneviève, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Service Hématologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Department of Ophthalmology, University Hospital Brest, and Université européenne de Bretagne - European University of Brittany (UEB)

Subjects
Oncology, medicine.medical_specialty, MESH: Combined Modality Therapy, [SDV.IMM] Life Sciences [q-bio]/Immunology, medicine.medical_treatment, MESH: Eye Neoplasms, 03 medical and health sciences, 0302 clinical medicine, MESH: Aged, 80 and over, Internal medicine, Medicine, Combined Modality Therapy, ComputingMilieux_MISCELLANEOUS, MESH: Aged, Chemotherapy, Hematology, MESH: Humans, business.industry, General Medicine, medicine.disease, MESH: Injections, Intravenous, 3. Good health, Radiation therapy, MESH: Antineoplastic Combined Chemotherapy Protocols, Local radiotherapy, 030220 oncology & carcinogenesis, MESH: Radiotherapy, Conformal, 030221 ophthalmology & optometry, Combined therapy, [SDV.IMM]Life Sciences [q-bio]/Immunology, Intraocular lymphoma, MESH: Platinum Compounds, business, MESH: Lymphoma
Abstract

International audience

Published
2011

2. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

Author

Soussain, Carole, Hoang-Xuan, Khê, Taillandier, Luc, Fourme, Emmanuelle, Choquet, Sylvain, Witz, Francis, Casasnovas, Olivier, Dupriez, Brigitte, Souleau, Bertrand, Taksin, Anne-Laure, Gisselbrecht, Christian, Jaccard, Arnaud, Omuro, Antonio, Sanson, Marc, Janvier, Maud, Kolb, Brigitte, Zini, Jean-Marc, Leblond, Véronique, Renseigné, Non, Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Réseau d'Etude des Gliomes, REG, Service de Neuro-Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie biologique [CHU Limoges], CHU Limoges, UPMC - Département de neurologie 2 - Mazarin, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, Oncology, Cancer Research, MESH: Combined Modality Therapy, MESH: Busulfan, medicine.medical_treatment, Salvage therapy, Hematopoietic stem cell transplantation, MESH: Eye Neoplasms, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, MESH: Cytarabine, Prospective Studies, Etoposide, MESH: Etoposide, MESH: Aged, MESH: Middle Aged, Brain Neoplasms, MESH: Thiotepa, Cytarabine, Hematopoietic Stem Cell Transplantation, Middle Aged, Combined Modality Therapy, 3. Good health, MESH: Salvage Therapy, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Lymphoma, Large B-Cell, Diffuse, Intraocular lymphoma, Stem cell, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, medicine.medical_specialty, MESH: Survival Rate, 03 medical and health sciences, Multicenter trial, Internal medicine, medicine, Humans, Busulfan, Cyclophosphamide, MESH: Hematopoietic Stem Cell Transplantation, Aged, Salvage Therapy, Chemotherapy, MESH: Humans, business.industry, Eye Neoplasms, MESH: Cyclophosphamide, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, Lymphoma, MESH: Lymphoma, Large B-Cell, Diffuse, Methotrexate, Neoplasm Recurrence, Local, business, human activities, MESH: Female, Thiotepa, 030217 neurology & neurosurgery
Abstract

Purpose The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor. We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment. Patients and Methods Salvage treatment consisted of two cycles of high-dose cytarabine and etoposide (CYVE). Intensive chemotherapy combined thiotepa, busulfan, and cyclophosphamide. Forty-three patients (median age, 52 years; range, 23 to 65 years) were included, with relapse (n = 22), refractory disease (n = 17), or a partial response to first-line treatment (n = 4). The response to CYVE was not assessable in three cases because of treatment-related death. Twenty patients (47%) were chemosensitive to CYVE: 15 of them proceeded to IC + HCR. IC + HCR was also administered to 12 patients who did not respond to CYVE. All but one of the 27 patients who underwent IC + HCR entered complete remission. Results With a median follow-up of 36 months, the median overall survival was 18.3 months in the overall population, and 58.6 months among patients who completed IC + HCR. The respective median progression-free survival (PFS) times after IC + HCR were 11.6 and 41.1 months. The 2-year overall survival probability was 45% in the whole population and 69% among the 27 patients who received IC + HCR. The 2-year PFS probability was 43% among all the patients and 58% in the IC + HCR subpopulation. Conclusion IC + HCR is an effective treatment for refractory and recurrent PCNSL.

Published
2008

3. Human papillomavirus: cause of epithelial lacrimal sac neoplasia?

Author

Patricia Cassonnet, Steffen Heegaard, Gérard Orth, Patricia Flamant, Jan Ulrik Prause, Nicolai Christian Sjö, Christian von Buchwald, Bodil Norrild, Eye Pathology Institute, Eye Pathology Institute-University of Copenhagen = Københavns Universitet (KU), Department of Otorhinolaryngology, Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Papillomavirus, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute of Medical Cell Biology and Genetics, Institute of Medical Cell Biology and Genetics-University of Copenhagen = Københavns Universitet (KU), University of Copenhagen = Københavns Universitet (KU)-Institute of Medical Cell Biology and Genetics, Eye Pathology Institute-University of Copenhagen = Københavns Universitet (UCPH), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institute of Medical Cell Biology and Genetics-University of Copenhagen = Københavns Universitet (UCPH)

Subjects
Male, MESH: Human papillomavirus 11, MESH: Carcinoma, Pathology, MESH: DNA Replication, MESH: Human papillomavirus 6, MESH: Papillomavirus Infections, MESH: Eye Neoplasms, Polymerase Chain Reaction, law.invention, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Autoradiography, law, In Situ Hybridization, Polymerase chain reaction, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Lacrimal Apparatus Diseases, Human papillomavirus 11, HPV infection, virus diseases, MESH: Carcinoma, Squamous Cell, Middle Aged, Lacrimal sac, female genital diseases and pregnancy complications, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, MESH: RNA, Viral, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Carcinoma, Squamous Cell, RNA, Viral, Female, Adult, DNA Replication, medicine.medical_specialty, In situ hybridization, MESH: Lacrimal Apparatus Diseases, Biology, 03 medical and health sciences, MESH: In Situ Hybridization, medicine, Carcinoma, Humans, Aged, MESH: Carcinoma, Transitional Cell, Carcinoma, Transitional Cell, MESH: Humans, Papilloma, Eye Neoplasms, Papillomavirus Infections, MESH: Adult, MESH: Polymerase Chain Reaction, Transitional epithelium, Human papillomavirus 6, medicine.disease, Dacryocystitis, MESH: Male, MESH: DNA, Viral, Ophthalmology, DNA, Viral, 030221 ophthalmology & optometry, Autoradiography, MESH: Papilloma, MESH: Female
Abstract

Purpose: Epithelial tumours of the lacrimal sac are rare but important entities that may carry grave prognoses. In this study the prevalence and possible role of human papillomavirus (HPV) infection in epithelial tumours of the lacrimal sac were evaluated. Methods: Five papillomas and six carcinomas of the lacrimal sac were investigated for the presence of HPV using the polymerase chain reaction (PCR) technique. Fifteen specimens of dacryocystitis were included in the PCR reactions as controls. Furthermore, DNA in situ hybridization (ISH) and RNA ISH were performed. Results: Low-risk HPV types 6 or 11 were identified in all four lacrimal sac papillomas suitable for PCR analysis and in situ hybridization. Four of six lacrimal sac carcinomas harboured HPV. One carcinoma was positive for HPV 11 only, two carcinomas had concomitant infection with HPV 6 or 11 and high-risk HPV 16, and the remaining carcinoma was positive for HPV 16. All specimens of dacryocystitis were betaglobin-positive and HPV-negative. Using DNA ISH, two papillomas and a single carcinoma showed evidence for vegetative HPV 11 DNA replication, whereas no HPV 16 DNA replication was found in the five carcinomas tested. HPV 11 RNA was demonstrated in two papillomas. Conclusions: By analysing 11 epithelial lacrimal sac papillomas and carcinomas using PCR, DNA ISH and RNA ISH, we found HPV DNA in all investigated transitional epithelium tumours of the lacrimal sac. HPV RNA was present in two of eight epithelial lacrimal sac tumours positive for HPV DNA. As RNA degrades fast in paraffin-embedded tissue, only a small fraction of DNA-positive tumours can be expected to be RNA-positive. We therefore suggest that HPV infection is associated with the development of lacrimal sac papillomas and carcinomas.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results